JUMP Expanded-Access Study for Intermediate or High-Risk Myelofibrosis | Jakafi®/Jakafi XR™ (ruxolitinib) Skip to main content
Visual representation of splenomegaly in myelofibrosis Illustration of enlarged spleen in a glass display

Spleen image is for illustrative purposes only and is not intended to represent actual patient spleen size.

JAKAFI® (ruxolitinib) safety and tolerability data: JUMP expanded-access study

JUMP study design1

  • JUMP was a single-arm, open-label, phase 3b, expanded-access study that enrolled adult patients with primary or secondary MF classified as intermediate-1–, intermediate-2–, or high-risk MF. Patients with intermediate-1–risk MF were required to have a palpable spleen (≥5 cm from the costal margin)
    • The study enrolled 2233 patients. At study entry, 835 patients had intermediate-1–risk MF, 755 patients had intermediate-2–risk MF, and 194 patients had high-risk MF*†
  • The primary endpoint was assessment of JAKAFI safety and tolerability by the frequency, duration, and severity of AEs. Additional endpoints included the proportion of patients with ≥50% reduction in palpable spleen length
  • *DIPSS scores were determined using patient characteristics at baseline. Results are based on a 07/05/17 cutoff date.1
  • †Patients who were not classified into a risk group (n=389) and patients with low-risk MF (n=60) are not included in the data shown.1

JUMP hematologic AEs1,2

Hematologic AEs 
(≥5% of Patients)
Full Cohort (N=2233)Intermediate-1–Risk MF
(n=835)
Intermediate-2– and 
High-Risk MF (n=949)
All Grades, %Grades 3 and 4, %All Grades, %Grades 3 and 4, %All Grades, %Grades 3 and 4, %
Anemia603557236347
Thrombocytopenia541943124720
Neutropenia756486

JUMP nonhematologic AEs1,2

Nonhematologic AEs 
(≥5% of Patients)
Full Cohort (N=2233)Intermediate-1–Risk MF 
(n=835)
Intermediate-2– and 
High-Risk MF (n=949)
All Grades, %Grades 3 and 4, %All Grades, %Grades 3 and 4, %All Grades, %Grades 3 and 4, %
Diarrhea131111141
Pyrexia162141184
Fatigue101101111
Asthenia152162142
Peripheral edema918191
Headache9012060
Dyspnea8282103
Abdominal pain817192
Nausea606060
Cough909080
Arthralgia8110171
Pain in extremity717170
Nasopharyngitis506050
Urinary tract infection617162
Pruritus607050
Constipation606050
Pneumonia7564106
Dizziness505060
Epistaxis505061

In the overall JUMP population, the safety profile was generally consistent with previous reports for JAKAFI1

  • 58% of all enrolled patients (n=1283) completed treatment per protocol1
    • Completing treatment was defined as undergoing treatment for up to 24 months after the last patient's first visit or transitioning to a commercial drug
  • The most common AEs leading to discontinuation were thrombocytopenia (3%, 58/1784) and anemia (2%, 35/1784)2

JUMP efficacy data: exploratory analysis

Reduction in spleen length by disease severity

Reduction in Palpable Spleen Length Over Time (Intermediate-1–Risk MF and Intermediate-2– and High-Risk MF)1,2,a

Limitations: This analysis is exploratory in nature and these results should be interpreted with caution

Graph Palpable Spleen Length Over Time

67%

(423/636) of patients had ≥50% reduction in spleen length at week 961

Most patients with Intermediate-1–risk MF had a ≥50% reduction in palpable spleen1

Best Percentage Change From Baseline in Palpable Spleen Length Through Study End in Patients With Intermediate-1–Risk MF2,a

Limitations: This analysis is exploratory in nature and these results should be interpreted with caution

Graph Spleen Length Percentage Change From Baseline

99%

of patients experienced a reduction in palpable spleen length through the end of the study2

AE=adverse event; DIPSS=Dynamic International Prognostic Scoring System; JAK=Janus kinase; JUMP=JAK Inhibitor RUxolitinib in Myelofibrosis Patients; MF=myelofibrosis; MPN=myeloproliferative neoplasm.

References: 1. Al-Ali HK, Griesshammer M, Foltz L, et al. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol. 2020;189(5):888-903. 2. Data on file. Incyte Corporation. Wilmington, DE.

 
 

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Thrombocytopenia, Anemia and Neutropenia

  • JAKAFI®/JAKAFI XR™ (ruxolitinib) can cause dose‑related effects of thrombocytopenia, anemia and neutropenia. Perform a pre‑treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated.
  • Manage thrombocytopenia by reducing the dose or temporarily interrupting JAKAFI/JAKAFI XR. Platelet transfusions may be necessary.
  • Patients developing anemia may require blood transfusions and/or dose modifications of JAKAFI/JAKAFI XR.
  • Severe neutropenia (ANC <0.5 × 109/L) was generally reversible by withholding JAKAFI/JAKAFI XR until recovery.

INDICATIONS AND USAGE

JAKAFI®/JAKAFI XR™ (ruxolitinib) is for treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.

JAKAFI/JAKAFI XR is for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.

JAKAFI/JAKAFI XR is for treatment of steroid‑refractory acute graft‑versus‑host disease (aGVHD) in adult and pediatric patients 12 years and older.

JAKAFI/JAKAFI XR is for treatment of chronic graft‑versus‑host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

Risk of Infection

  • Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting JAKAFI/JAKAFI XR until active serious infections have resolved. Observe patients receiving JAKAFI/JAKAFI XR for signs and symptoms of infection and manage promptly.

Tuberculosis

  • Tuberculosis (TB) infection with JAKAFI/JAKAFI XR has been reported. Observe patients taking JAKAFI/JAKAFI XR for signs and symptoms of active TB and manage promptly. Prior to initiating, evaluate patients for TB risk factors and test those at higher risk for latent infection. Consult a physician with expertise in the treatment of TB before starting in patients with evidence of active or latent TB. Continuation during treatment of active TB should be based on the overall risk‑benefit determination.

Progressive Multifocal Leukoencephalopathy

  • Progressive multifocal leukoencephalopathy (PML) has occurred with JAKAFI/JAKAFI XR treatment. If PML is suspected, stop JAKAFI/JAKAFI XR and evaluate.

Herpes Zoster and Herpes Simplex

  • Herpes zoster infection, reactivation and/or dissemination has been reported in patients receiving JAKAFI/JAKAFI XR. Advise patients about early signs and symptoms of herpes zoster and seek treatment. Monitor patients for the development of herpes simplex infections. If a patient develops evidence of dissemination of herpes simplex, consider interrupting treatment.

Hepatitis B

  • Increases in hepatitis B viral load with or without associated elevations in alanine aminotransferase and aspartate aminotransferase have been reported in patients with chronic hepatitis B virus (HBV) infections.

Symptom Exacerbation Following Interruption or Discontinuation of Treatment

  • When discontinuing JAK‑Inhibitors, including JAKAFI/JAKAFI XR, myeloproliferative neoplasm‑related signs and symptoms may flare. After discontinuation, some patients with myelofibrosis have experienced fever, respiratory distress, hypotension, disseminated intravascular coagulation (DIC), or multi‑organ failure. If any of these occur after discontinuation or while tapering JAKAFI/JAKAFI XR, evaluate and treat any intercurrent illness and consider restarting or increasing the dose. Instruct patients not to interrupt or discontinue JAKAFI/JAKAFI XR without consulting their physician. When discontinuing or interrupting JAKAFI/JAKAFI XR for reasons other than life‑threatening toxicities, consider gradual tapering rather than abrupt discontinuation.

Non‑Melanoma Skin Cancer (NMSC)

  • NMSC including basal cell, squamous cell, and Merkel cell carcinoma have occurred. Perform periodic skin examinations.

Lipid Elevations

  • Treatment with JAKAFI/JAKAFI XR has been associated with increases in total cholesterol, low‑density lipoprotein cholesterol, and triglycerides. Assess lipid parameters 8‑12 weeks after initiation.

Major Adverse Cardiovascular Events (MACE)

  • Another JAK‑inhibitor has increased the risk of major adverse cardiovascular events (MACE), including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers), in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur.

Thrombosis

  • Another JAK‑inhibitor has increased the risk of thrombosis, including deep venous thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis (compared to those treated with TNF blockers), in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. In patients with myelofibrosis (MF) and polycythemia vera (PV), the rates of thromboembolic events were similar in JAKAFI/JAKAFI XR and control treated patients. Patients with symptoms of thrombosis should be promptly evaluated and treated appropriately.

Secondary Malignancies

  • Another JAK‑inhibitor has increased the risk of lymphoma and other malignancies, excluding NMSC (compared to those treated with TNF blockers), in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. Patients who are current or past smokers are at additional increased risk.

Adverse Reactions

  • In myelofibrosis, the most common hematologic adverse reactions (incidence >20%) were thrombocytopenia and anemia. The most common nonhematologic adverse reactions (incidence ≥15%) were bruising, dizziness and headache.
  • In polycythemia vera, the most common hematologic adverse reactions (incidence >20%) were anemia and thrombocytopenia. The most common nonhematologic adverse reactions (incidence ≥15%) were diarrhea and dizziness.
  • In acute graft‑versus‑host disease, the most common hematologic adverse reactions (incidence >50%) were anemia, thrombocytopenia and neutropenia. The most common nonhematologic adverse reactions (incidence >50%) were infections (pathogen not specified) and edema.
  • In chronic graft‑versus‑host disease, the most common hematologic adverse reactions (incidence >35%) were anemia and thrombocytopenia. The most common nonhematologic adverse reactions (incidence ≥20%) were infections (pathogen not specified) and viral infections.

Drug Interactions

  • Avoid concomitant use with fluconazole doses greater than 200 mg. Dose modifications may be required when administering fluconazole doses of 200 mg or less, or with strong CYP3A4 inhibitors, or in patients with renal or hepatic impairment. Patients should be closely monitored and the dose titrated based on safety and efficacy.

Pregnancy

  • Use during pregnancy is not recommended and should only be used if the potential benefit justifies the potential risk to the fetus. Women taking JAKAFI/JAKAFI XR should not breastfeed during treatment and for 2 weeks after the final dose.

Please see Full Prescribing Information for JAKAFI/JAKAFI XR.